GlassScriptPhysician profile
Roger J Kruse
NPI 1487650339
$2,050.84
in general payments reported to CMS, 2019-2025
28 companies · $245 in 2025
The $245 reported for 2025 was more than what a typical Sports Medicine (Family Medicine) provider received nationally (typical 2025 total: $113).
See the full distribution for Sports Medicine (Family Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $385 · 2020: $95.07 · 2021: $444 · 2022: $250 · 2023: $263 · 2024: $368 · 2025: $245.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $876.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $876.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $370.80 | 2019-2025 | |
| Trice Medical, INC. | $368.06 | 2023-2025 | |
| Pacira Therapeutics, INC. | $233.28 | 2019-2021 | |
| Abbvie INC. | $149.92 | 2021-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $143.00 | 2022 | |
| Tenex Health INC. | $115.16 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $80.90 | 2021 | |
| Merz North America, INC. | $74.99 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $58.70 | 2021 | |
| Novo Nordisk INC | $56.54 | 2020-2025 | |
| Amgen INC. | $38.12 | 2019 | |
| Axsome Therapeutics, INC. | $32.50 | 2023 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $31.15 | 2021-2022 | |
| Boston Scientific Corporation | $28.97 | 2023 | Superion Indirect Decompression System |
| Biodelivery Sciences International, INC. | $28.72 | 2020-2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $28.35 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $28.31 | 2020-2022 | |
| Ossur Americas, INC. | $27.95 | 2024 | Miami J |
| Collegium Pharmaceutical, INC. | $25.07 | 2019 | |
| Almatica Pharma LLC | $20.81 | 2021 | |
| Ge Healthcare | $17.60 | 2022 | |
| Lilly USA, LLC | $16.60 | 2025 | Zepbound, Mounjaro |
| Avanos Medical | $13.95 | 2019 | |
| Daiichi Sankyo INC. | $13.92 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $12.95 | 2019 | |
| Depuy Synthes Sales INC. | $12.22 | 2020 | |
| Glaxosmithkline, LLC. | $11.84 | 2022 | |
| Corium, LLC | $10.46 | 2025 | Azstarys |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roger Kruse listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.